GLP-1 Medications and Cancer Risk: What a New Study Shows
GLP-1 Medications and Cancer Risk: What a New Study Shows
Published May 26, 2026 | Dr. Ethan Lazarus, MD
A new study adds to a growing body of evidence that GLP-1 receptor agonists may do more than lower blood sugar and reduce body weight — they may also lower cancer risk.
Presented at Digestive Disease Week (DDW) 2026 in Chicago, researchers from Houston Methodist Hospital analyzed data from more than 46,000 patients with obesity and found that those treated with semaglutide or tirzepatide had a significantly lower incidence of cancer compared to untreated patients over a 5-year period.
The Numbers
The study used the TriNetX database, matching 46,142 treated patients with 46,142 untreated patients with similar obesity profiles. All patients were aged 18–75 with a BMI of 30 or higher.
Key findings:
- Overall cancer incidence: 7.5% in the treated group vs. 9.1% in the untreated group — a statistically significant reduction (HR 0.92; 95% CI, 0.88–0.96)
- Skin cancer risk: Particularly striking — a 25% reduction in risk (HR 0.75; 95% CI, 0.66–0.85)
- Gastrointestinal, pancreatic, and hepatobiliary cancers: No significant difference between groups
The mean age of participants was 51, and 56% were women.
What This Means in Context
The 8% reduction in overall cancer risk is meaningful, though it’s important to understand what it does and doesn’t prove.
This was a retrospective cohort study — strong for identifying associations, but not definitive proof of causation. The researchers acknowledged the need for large-scale prospective randomized trials to confirm these findings. That said, a 25% reduction in skin cancer risk is a signal worth taking seriously.
Several biological mechanisms may explain these findings:
Reduced inflammation. Obesity is a chronic inflammatory state that promotes carcinogenesis. GLP-1 receptor activation has demonstrated anti-inflammatory effects in multiple tissue types.
Weight loss itself. Carrying excess weight is a well-established risk factor for at least 13 types of cancer. Sustained weight loss reduces that exposure over time.
Direct cellular effects. GLP-1 receptors are expressed in a range of tissues. Animal data suggest GLP-1 receptor activation may directly inhibit tumor cell proliferation and promote apoptosis in some cancer models.
The Practical Takeaway for Patients
These data do not change the current standard of care, but they add to the case for treating obesity aggressively rather than watching and waiting. The health benefits of GLP-1 therapy appear to extend beyond the numbers on the scale.
For patients already on or considering GLP-1 therapy, this study is reassuring — not just for weight and metabolic health, but potentially for long-term cancer risk as well. The absence of increased risk in gastrointestinal and pancreatic cancers (areas that have received some theoretical concern) is particularly relevant for a clinician audience.
For patients who have been hesitant about GLP-1 medications due to safety concerns, this study adds to a substantial body of evidence supporting their safety profile — and now hints at a potential protective effect.
What Comes Next
The authors appropriately called for prospective randomized trials. Several are already underway. The oncology community is watching this space closely.
In the meantime, treating obesity effectively — whether with GLP-1 medications, lifestyle intervention, or both — remains one of the most powerful cancer prevention strategies available. It is estimated that obesity contributes to approximately 4% of all cancers in the United States.
Dr. Ethan Lazarus is a double board-certified physician in Obesity Medicine and Family Medicine and the founder of the Clinical Nutrition Center in Greenwood Village, Colorado.
